AG
VYGR icon

Algert Global’s Voyager Therapeutics VYGR Stock Holding History

Algert Global’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-28,650
Closed -$218K – 1401
2022
Q1 		$218K Sell
28,650
-2,840
-9% -$12.7K 0.01% 1034
2021
Q4 		$85K Buy
31,490
+16,170
+106% +$55.2K 0.01% 924
2021
Q3 		$40K Buy
+15,320
New +$49.8K 0.01% 1001
2020
Q4 		– Sell
-28,955
Closed -$309K – 504
2020
Q3 		$309K Hold
28,955
– – 0.1% 253
2020
Q2 		$365K Sell
28,955
-59,410
-67% -$691K 0.12% 242
2020
Q1 		$809K Buy
88,365
+610
+0.7% +$7K 0.34% 113
2019
Q4 		$1.22M Buy
87,755
+49,540
+130% +$720K 0.37% 101
2019
Q3 		$658K Buy
38,215
+12,110
+46% +$254K 0.25% 128
2019
Q2 		$711K Buy
26,105
+9,715
+59% +$222K 0.26% 127
2019
Q1 		$314K Buy
+16,390
New +$213K 0.18% 183

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Algert Global's VYGR Position: Q2 2022 in Review

Algert Global sold out of Voyager Therapeutics (VYGR) in Q2 2022, closing a stake of 28,650 shares — an estimated $218K sold.

Algert Global first reported a position in VYGR in Q1 2019 and held it in 10 quarters. The position peaked at $1.22M in Q4 2019. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2022.

  • Algert Global reported no remaining Voyager Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Algert Global sold 28,650 Voyager Therapeutics shares in Q2 2022, an estimated $218K.
  • Algert Global first reported a position in Voyager Therapeutics in Q1 2019 and held it in 10 quarters.
  • Algert Global's Voyager Therapeutics position peaked at $1.22M in Q4 2019.
  • 78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2022.

Based on Algert Global's 13F filing for Q2 2022, filed 15 Aug 2022.